AngioDynamics, Inc. (ANGO)
USD 8.93
(-3.56%)
USD 8.93
(-3.56%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -70.14 Million USD | -1472.22% |
| 2023 | 5.19 Million USD | 4.84% |
| 2022 | 4.95 Million USD | 117.61% |
| 2021 | -28.16 Million USD | -107.08% |
| 2020 | -13.59 Million USD | 85.07% |
| 2019 | -91.09 Million USD | -564.2% |
| 2018 | 19.62 Million USD | -66.4% |
| 2017 | 58.4 Million USD | -42.74% |
| 2016 | 101.99 Million USD | -21.08% |
| 2015 | 129.23 Million USD | -9.56% |
| 2014 | 142.89 Million USD | 10.0% |
| 2013 | 129.9 Million USD | 2.7% |
| 2012 | 126.49 Million USD | 420.77% |
| 2011 | -39.43 Million USD | 24.1% |
| 2010 | -51.95 Million USD | -149.37% |
| 2009 | -20.83 Million USD | -39.59% |
| 2008 | -14.92 Million USD | -37.14% |
| 2007 | -10.88 Million USD | 82.19% |
| 2006 | -61.1 Million USD | -436.12% |
| 2005 | -11.39 Million USD | -352.84% |
| 2004 | 4.5 Million USD | -75.77% |
| 2003 | 18.6 Million USD | 27.22% |
| 2002 | 14.62 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -52.85 Million USD | -1116.87% |
| 2024 FY | -70.14 Million USD | -1449.4% |
| 2024 Q3 | -74.48 Million USD | -31.42% |
| 2024 Q2 | -56.67 Million USD | -7.23% |
| 2024 Q4 | -70.14 Million USD | 5.83% |
| 2023 Q4 | 5.19 Million USD | -82.42% |
| 2023 Q3 | 29.57 Million USD | 48.32% |
| 2023 Q2 | 19.93 Million USD | -41.57% |
| 2023 Q1 | 34.12 Million USD | 588.3% |
| 2023 FY | 5.19 Million USD | 4.84% |
| 2022 Q1 | -10.47 Million USD | 62.81% |
| 2022 FY | 4.95 Million USD | 117.61% |
| 2022 Q2 | -9.29 Million USD | 11.28% |
| 2022 Q4 | 4.95 Million USD | 346.67% |
| 2022 Q3 | 1.11 Million USD | 111.95% |
| 2021 Q1 | -7.92 Million USD | 41.69% |
| 2021 Q4 | -28.16 Million USD | -15.09% |
| 2021 Q2 | -18.02 Million USD | -127.33% |
| 2021 Q3 | -24.46 Million USD | -35.75% |
| 2021 FY | -28.16 Million USD | -107.08% |
| 2020 FY | -13.59 Million USD | 85.07% |
| 2020 Q2 | -40.35 Million USD | 51.24% |
| 2020 Q3 | -11.93 Million USD | 70.44% |
| 2020 Q4 | -13.59 Million USD | -13.99% |
| 2020 Q1 | -82.77 Million USD | 9.14% |
| 2019 Q2 | 105.45 Million USD | 51.39% |
| 2019 Q1 | 69.65 Million USD | 254.93% |
| 2019 FY | -91.09 Million USD | -564.2% |
| 2019 Q3 | 98.05 Million USD | -7.01% |
| 2019 Q4 | -91.09 Million USD | -192.91% |
| 2018 FY | 19.62 Million USD | -66.4% |
| 2018 Q1 | 56.58 Million USD | -3.11% |
| 2018 Q2 | 46.17 Million USD | -18.39% |
| 2018 Q3 | 42.58 Million USD | -7.78% |
| 2018 Q4 | 19.62 Million USD | -53.92% |
| 2017 Q3 | 71.47 Million USD | -19.63% |
| 2017 FY | 58.4 Million USD | -42.74% |
| 2017 Q4 | 58.4 Million USD | -18.3% |
| 2017 Q2 | 88.93 Million USD | -5.18% |
| 2017 Q1 | 93.79 Million USD | -8.04% |
| 2016 Q3 | 117.16 Million USD | -6.03% |
| 2016 Q4 | 101.99 Million USD | -12.95% |
| 2016 Q1 | 126.12 Million USD | -2.41% |
| 2016 FY | 101.99 Million USD | -21.08% |
| 2016 Q2 | 124.68 Million USD | -1.14% |
| 2015 FY | 129.23 Million USD | -9.56% |
| 2015 Q4 | 129.23 Million USD | -7.07% |
| 2015 Q3 | 139.07 Million USD | -7.33% |
| 2015 Q2 | 150.07 Million USD | 8.24% |
| 2015 Q1 | 138.64 Million USD | -2.97% |
| 2014 Q2 | 137.2 Million USD | 3.06% |
| 2014 FY | 142.89 Million USD | 10.0% |
| 2014 Q3 | 143.67 Million USD | 4.71% |
| 2014 Q4 | 142.89 Million USD | -0.54% |
| 2014 Q1 | 133.13 Million USD | 2.49% |
| 2013 FY | 129.9 Million USD | 2.7% |
| 2013 Q4 | 129.9 Million USD | -5.09% |
| 2013 Q2 | 134.98 Million USD | 3.27% |
| 2013 Q1 | 130.7 Million USD | 3.33% |
| 2013 Q3 | 136.87 Million USD | 1.4% |
| 2012 Q1 | -44 Million USD | -11.6% |
| 2012 Q2 | -36.54 Million USD | 16.97% |
| 2012 Q3 | -27.7 Million USD | 24.19% |
| 2012 Q4 | 126.49 Million USD | 556.62% |
| 2012 FY | 126.49 Million USD | 420.77% |
| 2011 Q3 | -28.64 Million USD | -40.04% |
| 2011 Q1 | -60.45 Million USD | -16.37% |
| 2011 FY | -39.43 Million USD | 24.1% |
| 2011 Q4 | -39.43 Million USD | -37.68% |
| 2011 Q2 | -20.45 Million USD | 66.17% |
| 2010 Q3 | -30.64 Million USD | -4.49% |
| 2010 Q4 | -51.95 Million USD | -69.54% |
| 2010 FY | -51.95 Million USD | -149.37% |
| 2010 Q2 | -29.32 Million USD | -16.47% |
| 2010 Q1 | -25.17 Million USD | -20.85% |
| 2009 Q3 | -19.61 Million USD | -57.07% |
| 2009 Q4 | -20.83 Million USD | -6.21% |
| 2009 FY | -20.83 Million USD | -39.59% |
| 2009 Q2 | -12.48 Million USD | -11.63% |
| 2009 Q1 | -11.18 Million USD | 25.04% |
| 2008 Q2 | -5.47 Million USD | 9.76% |
| 2008 Q4 | -14.92 Million USD | 43.56% |
| 2008 Q3 | -26.44 Million USD | -383.12% |
| 2008 FY | -14.92 Million USD | -37.14% |
| 2008 Q1 | -6.06 Million USD | 44.26% |
| 2007 Q1 | -67.89 Million USD | -11.11% |
| 2007 Q4 | -10.88 Million USD | 47.05% |
| 2007 Q3 | -20.55 Million USD | 70.77% |
| 2007 Q2 | -70.31 Million USD | -3.56% |
| 2007 FY | -10.88 Million USD | 82.19% |
| 2006 Q4 | -61.1 Million USD | -488.93% |
| 2006 Q2 | -10.02 Million USD | 2.06% |
| 2006 Q1 | -10.23 Million USD | 10.21% |
| 2006 FY | -61.1 Million USD | -436.12% |
| 2006 Q3 | -10.37 Million USD | -3.52% |
| 2005 Q3 | -12.26 Million USD | -41.47% |
| 2005 Q1 | -17.52 Million USD | -488.84% |
| 2005 Q2 | -8.66 Million USD | 50.54% |
| 2005 FY | -11.39 Million USD | -352.84% |
| 2005 Q4 | -11.39 Million USD | 7.06% |
| 2004 Q4 | 4.5 Million USD | -75.1% |
| 2004 Q3 | 18.1 Million USD | 0.0% |
| 2004 FY | 4.5 Million USD | -75.77% |
| 2003 FY | 18.6 Million USD | 27.22% |
| 2003 Q4 | 18.6 Million USD | 0.0% |
| 2002 FY | 14.62 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 2.58 Million USD | 2817.629% |
| AtriCure, Inc. | -9.81 Million USD | -614.568% |
| Avinger, Inc. | 10.12 Million USD | 793.103% |
| Azenta, Inc. | -618.47 Million USD | 88.659% |
| BioLife Solutions, Inc. | 7.25 Million USD | 1067.076% |
| The Cooper Companies, Inc. | 2.44 Billion USD | 102.865% |
| Daxor Corporation | 755.65 Thousand USD | 9382.229% |
| Ekso Bionics Holdings, Inc. | -1.47 Million USD | -4671.565% |
| Femasys Inc. | -15.01 Million USD | -367.14% |
| GlucoTrack, Inc. | -4.29 Million USD | -1532.728% |
| Harvard Bioscience, Inc. | 38.49 Million USD | 282.234% |
| Hologic, Inc. | 374.4 Million USD | 118.735% |
| ICU Medical, Inc. | 1.45 Billion USD | 104.836% |
| Intuitive Surgical, Inc. | -2.66 Billion USD | 97.363% |
| KORU Medical Systems, Inc. | -7.03 Million USD | -896.743% |
| LeMaitre Vascular, Inc. | -5.17 Million USD | -1255.663% |
| Innovative Eyewear, Inc. | -4.28 Million USD | -1535.985% |
| Innovative Eyewear, Inc. | -4.28 Million USD | -1535.985% |
| Masimo Corporation | 804 Million USD | 108.724% |
| Microbot Medical Inc. | -2.28 Million USD | -2968.329% |
| Meihua International Medical Technologies Co., Ltd. | -9.59 Million USD | -630.97% |
| Merit Medical Systems, Inc. | 302.22 Million USD | 123.209% |
| Nephros, Inc. | -2.47 Million USD | -2738.608% |
| NovoCure Limited | 355.42 Million USD | 119.735% |
| NEXGEL, Inc. | 98 Thousand USD | 71673.469% |
| NEXGEL, Inc. | 98 Thousand USD | 71673.469% |
| Singular Genomics Systems, Inc. | 59.05 Million USD | 218.774% |
| OraSure Technologies, Inc. | -276.9 Million USD | 74.669% |
| Pro-Dex, Inc. | 10.91 Million USD | 742.561% |
| Pulse Biosciences, Inc. | -35.22 Million USD | -99.148% |
| Predictive Oncology Inc. | -5.87 Million USD | -1094.548% |
| Precision Optics Corporation, Inc. | 3.02 Million USD | 2415.542% |
| QuidelOrtho Corporation | 2.49 Billion USD | 102.811% |
| Repligen Corporation | -39.51 Million USD | -77.489% |
| Sanara MedTech Inc. | 6.64 Million USD | 1155.577% |
| STAAR Surgical Company | -147.2 Million USD | 52.35% |
| Sharps Technology, Inc. | -3.01 Million USD | -2228.05% |
| Utah Medical Products, Inc. | -92.52 Million USD | 24.192% |
| DENTSPLY SIRONA Inc. | 1.96 Billion USD | 103.57% |
| Jin Medical International Ltd. | -2.81 Million USD | -2390.389% |